Jianhua Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianhua Zhu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Zhenwei Li
Department of Cardiology, Ningbo First Hospital, Ningbo 315000, China
5 shared publicationsShuai Wang
Department of Cardiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
4 shared publicationsWenting Zhao
Department of Cardiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
4 shared publicationsZewei Sun
Department of Cardiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
4 shared publicationsHui Yan
Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang, PR China
3 shared publicationsMingjie Wu
Department of Cardiology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
3 shared publications
Latest Publications
- Open Access
- 1 June 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 83, 106432
RBM4 regulates M1 macrophages polarization through targeting STAT1-mediated glycolysis
- 1 June 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 83, 106432
Open AccessRBM4 regulates M1 macrophages polarization through targeting STAT1-mediated glycolysis
- 1 June 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 71 (6) , 534-539
Midterm outcome of transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized controlled trials
- 1 June 2018
- Published by Elsevier in Journal of Cardiology
- Vol. 71 (6) , 534-539
Midterm outcome of transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized controlled trials
- Open Access
- 15 June 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 1-12
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
High on-treatment platelet reactivity (HPR) represents a strong risk factor for thrombotic events after PCI. We aim to evaluate the efficacy and safety of individualizing intensified dual antiplatelet therapy (DAPT) in PCI-treated patients with HPR based on platelet function testing (PFT). Electronic databases were searched for randomized control trials that reported the clinical outcomes of using an intensified antiplatelet protocol with P2Y12 receptor inhibitor comparing with standard maintenance dose of clopidogrel on the basis of platelet function testing. Clinical endpoints were assessed. From 2005 to 2016, thirteen clinical studies comprising 7290 patients were included for analysis. Compared with standard antiplatelet therapy with clopidogrel, the intensified protocol based on platelet function testing was associated with a significant reduction in major adverse cardiovascular events (RR:0.55, 95% CI: 0.36–0.84, p = 0.005), cardiovascular death (RR:0.60, 95% CI: 0.38–0.96, p = 0.03), stent thrombosis (RR:0.58, 95% CI: 0.36–0.93, p = 0.02) and target vessel revascularization (RR:0.33, 95% CI: 0.14–0.76, p = 0.009). No significant difference was found in the rate of bleeding events between intensified and standard protocol. Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding.
- 15 June 2017
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 17 (1) , 1-12
Open AccessIndividualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
High on-treatment platelet reactivity (HPR) represents a strong risk factor for thrombotic events after PCI. We aim to evaluate the efficacy and safety of individualizing intensified dual antiplatelet therapy (DAPT) in PCI-treated patients with HPR based on platelet function testing (PFT). Electronic databases were searched for randomized control trials that reported the clinical outcomes of using an intensified antiplatelet protocol with P2Y12 receptor inhibitor comparing with standard maintenance dose of clopidogrel on the basis of platelet function testing. Clinical endpoints were assessed. From 2005 to 2016, thirteen clinical studies comprising 7290 patients were included for analysis. Compared with standard antiplatelet therapy with clopidogrel, the intensified protocol based on platelet function testing was associated with a significant reduction in major adverse cardiovascular events (RR:0.55, 95% CI: 0.36–0.84, p = 0.005), cardiovascular death (RR:0.60, 95% CI: 0.38–0.96, p = 0.03), stent thrombosis (RR:0.58, 95% CI: 0.36–0.93, p = 0.02) and target vessel revascularization (RR:0.33, 95% CI: 0.14–0.76, p = 0.009). No significant difference was found in the rate of bleeding events between intensified and standard protocol. Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding.
- 1 February 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 228, 723-728
Transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized and observational studies
- 1 February 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 228, 723-728
Transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized and observational studies
- Open Access
- 19 August 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (4) , 2945-2952
Rspo2 suppresses CD36-mediated apoptosis in oxidized low density lipoprotein-induced macrophages
Oxidized low density lipoprotein (oxLDL)-induced apoptosis of macrophages contributes to the formation of atherosclerotic plaques. R‑spondin 2 (Rspo2), a member of the cysteine‑rich secreted proteins, has been shown to be involved in the oncogenesis of several types of cancer. It has also been found to be abundantly expressed among the four R‑spondin members in macrophages. The present study was performed to determine whether Rspo2 is involved in the ox‑LDL‑induced apoptosis of macrophages. It was identified that Rspo2 inhibited oxLDL‑induced apoptosis in the presence of endoplasmic reticulum (ER) stress activator using flow cytometry. In addition, Rspo2 was observed to suppress oxLDL‑induced ER stress and reactive oxygen species production as demonstrated by western blotting. Furthermore, analysis of the role of Rspo2 in macrophage lipid uptake identified that Rspo2 negatively regulated the Dil‑oxLDL uptake by inhibiting the expression of cluster of differentiation (CD)36, through the transcription factor, peroxisome proliferator‑activated receptor (PPAR)‑γ. The manipulation of Rspo2 had a direct effect on PPAR‑γ nuclear translocation. In addition, chromatin immunoprecipitation analysis revealed that Rspo2 manipulation led to regulation of the direct binding between PPAR‑γ and CD36. In conclusion, Rspo2 was found to have a negative regulatory effect during oxLDL‑induced macrophage apoptosis by regulating lipid uptake.
- 19 August 2016
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 14 (4) , 2945-2952
Open AccessRspo2 suppresses CD36-mediated apoptosis in oxidized low density lipoprotein-induced macrophages
Oxidized low density lipoprotein (oxLDL)-induced apoptosis of macrophages contributes to the formation of atherosclerotic plaques. R‑spondin 2 (Rspo2), a member of the cysteine‑rich secreted proteins, has been shown to be involved in the oncogenesis of several types of cancer. It has also been found to be abundantly expressed among the four R‑spondin members in macrophages. The present study was performed to determine whether Rspo2 is involved in the ox‑LDL‑induced apoptosis of macrophages. It was identified that Rspo2 inhibited oxLDL‑induced apoptosis in the presence of endoplasmic reticulum (ER) stress activator using flow cytometry. In addition, Rspo2 was observed to suppress oxLDL‑induced ER stress and reactive oxygen species production as demonstrated by western blotting. Furthermore, analysis of the role of Rspo2 in macrophage lipid uptake identified that Rspo2 negatively regulated the Dil‑oxLDL uptake by inhibiting the expression of cluster of differentiation (CD)36, through the transcription factor, peroxisome proliferator‑activated receptor (PPAR)‑γ. The manipulation of Rspo2 had a direct effect on PPAR‑γ nuclear translocation. In addition, chromatin immunoprecipitation analysis revealed that Rspo2 manipulation led to regulation of the direct binding between PPAR‑γ and CD36. In conclusion, Rspo2 was found to have a negative regulatory effect during oxLDL‑induced macrophage apoptosis by regulating lipid uptake.
- Open Access
- 29 December 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 13 (2) , 1709-1716
Oxidized low-density lipoprotein upregulates microRNA-146a via JNK and NF-κB signaling
Increasing evidence suggested the involvement of microRNA (miR)-146a in the pathogenesis of multiple diseases, including atherosclerosis, bacterial infection and cancer. However, the mechanism by which miR-146a is regulated in macrophages exposed to oxidized low-density lipoprotein (oxLDL) has remained elusive. The present study aimed to explore the molecular pathway of miR-146a regulation in response to oxLDL. Human THP-1 macrophages were pre-treated with small interfering RNA specific for scavenger receptors or with pharmacological inhibitors prior to oxLDL administration. A filter plate screening assay was performed to identify oxLDL-inducible transcription factors that bind to the miR-146a promoter. The exact binding sites were mapped by chromatin immunoprecipitation. The effects of miR-146a on markers of macrophage maturation were studied by flow cytometry. The results revealed that miR-146a expression was deceased when c-jun N-terminal kinase (JNK) or nuclear factor (NF)-κB signaling was inhibited. By forming a complex with c-jun, which was promoted by oxLDL, the NF-κB sub-unit p65 facilitated the binding of c-jun to the miR-146a promoter to trigger transcriptional activation. miR-146a negatively regulated macrophage maturation by reducing the expression of CD86 and CD80. The present study demonstrated that oxLDL positively regulates miR-146a via the JNK and NF-κB pathways in macrophages, and that miR-146a inhibits inflammatory activation.
- 29 December 2015
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 13 (2) , 1709-1716
Open AccessOxidized low-density lipoprotein upregulates microRNA-146a via JNK and NF-κB signaling
Increasing evidence suggested the involvement of microRNA (miR)-146a in the pathogenesis of multiple diseases, including atherosclerosis, bacterial infection and cancer. However, the mechanism by which miR-146a is regulated in macrophages exposed to oxidized low-density lipoprotein (oxLDL) has remained elusive. The present study aimed to explore the molecular pathway of miR-146a regulation in response to oxLDL. Human THP-1 macrophages were pre-treated with small interfering RNA specific for scavenger receptors or with pharmacological inhibitors prior to oxLDL administration. A filter plate screening assay was performed to identify oxLDL-inducible transcription factors that bind to the miR-146a promoter. The exact binding sites were mapped by chromatin immunoprecipitation. The effects of miR-146a on markers of macrophage maturation were studied by flow cytometry. The results revealed that miR-146a expression was deceased when c-jun N-terminal kinase (JNK) or nuclear factor (NF)-κB signaling was inhibited. By forming a complex with c-jun, which was promoted by oxLDL, the NF-κB sub-unit p65 facilitated the binding of c-jun to the miR-146a promoter to trigger transcriptional activation. miR-146a negatively regulated macrophage maturation by reducing the expression of CD86 and CD80. The present study demonstrated that oxLDL positively regulates miR-146a via the JNK and NF-κB pathways in macrophages, and that miR-146a inhibits inflammatory activation.
- 1 December 2015
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 89, 75-86
miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration
- 1 December 2015
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 89, 75-86
miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration
- 1 August 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 464 (1) , 1-6
miR-29a promotes scavenger receptor A expression by targeting QKI (quaking) during monocyte-macrophage differentiation
- 1 August 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 464 (1) , 1-6
miR-29a promotes scavenger receptor A expression by targeting QKI (quaking) during monocyte-macrophage differentiation
- Open Access
- 11 February 2015
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 35 (4) , 1289-1302
Wnt1 Positively Regulates CD36 Expression via TCF4 and PPAR-γ in Macrophages
Background: Scavenger receptors including CD36 control the phagocytosis of oxidized low-density lipoprotein and play an important role in macrophage physiology, but the underlying molecular mechanism by which CD36 is regulated in macrophages or during macrophage differentiation from monocytes remains to be determined. Methods: Here, we investigated the relationship between Wnt1 and CD36 during macrophage differentiation. CD36 was suppressed following knockdown of Wnt1 by siRNA, while it was increased by ectopic overexpression of Wnt1 in macrophages. Using a β-catenin inhibitor, peroxisome proliferator-activated receptor gamma (PPAR-γ) siRNA, and transcription factor 4 (TCF4) siRNA, we demonstrated that Wnt1 regulates the expression of CD36 through TCF4 and PPAR-γ. Co-immunoprecipitation, chromatin immunoprecipitation, and immunofluorescence experiments showed that β-catenin interacted with PPAR-γ and that PPAR-γ and TCF4 colocalized in the nucleus. Furthermore, Pax3 regulated Wnt1 via binding to the first binding site in the Wnt1 promoter. Results: Our study demonstrated that during macrophage differentiation from monocytes, Wnt1 promotes CD36 expression via activation of PPAR-γ and TCF4. Conclusions: Our findings suggest that Wnt1 plays an important role in macrophage physiology via activation of the canonical Wnt pathway.
- 11 February 2015
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 35 (4) , 1289-1302
Open AccessWnt1 Positively Regulates CD36 Expression via TCF4 and PPAR-γ in Macrophages
Background: Scavenger receptors including CD36 control the phagocytosis of oxidized low-density lipoprotein and play an important role in macrophage physiology, but the underlying molecular mechanism by which CD36 is regulated in macrophages or during macrophage differentiation from monocytes remains to be determined. Methods: Here, we investigated the relationship between Wnt1 and CD36 during macrophage differentiation. CD36 was suppressed following knockdown of Wnt1 by siRNA, while it was increased by ectopic overexpression of Wnt1 in macrophages. Using a β-catenin inhibitor, peroxisome proliferator-activated receptor gamma (PPAR-γ) siRNA, and transcription factor 4 (TCF4) siRNA, we demonstrated that Wnt1 regulates the expression of CD36 through TCF4 and PPAR-γ. Co-immunoprecipitation, chromatin immunoprecipitation, and immunofluorescence experiments showed that β-catenin interacted with PPAR-γ and that PPAR-γ and TCF4 colocalized in the nucleus. Furthermore, Pax3 regulated Wnt1 via binding to the first binding site in the Wnt1 promoter. Results: Our study demonstrated that during macrophage differentiation from monocytes, Wnt1 promotes CD36 expression via activation of PPAR-γ and TCF4. Conclusions: Our findings suggest that Wnt1 plays an important role in macrophage physiology via activation of the canonical Wnt pathway.